Debio-025 inhibits HIV-1 by interfering with an early event in the replication cycle

Antiviral Research

Volumn 85, Issue 2, 2010, Pages 418-421

  Daelemans, Dirk ^a   Dumont, Jean Maurice ^b   Rosenwirth, Brigitte ^c   De Clercq, Erik ^a   Pannecouque, Christophe ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b DEBIOPHARM SA   (Switzerland)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cyclophilin; Cyclosporine; Debio 025; HIV; Time of addition

Indexed keywords

CAPSID PROTEIN; CYCLOPHILIN; CYCLOSPORIN A; CYCLOSPORIN A [3 N METHYL DEXTRO ALANINE 4 N ETHYLVALINE]; NEVIRAPINE;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; VIRUS CAPSID; VIRUS ENTRY; VIRUS INHIBITION; VIRUS INTERFERENCE; VIRUS MUTANT; VIRUS REPLICATION; VIRUS STRAIN;

ANTI-HIV AGENTS; CAPSID; CYCLOPHILIN A; CYCLOSPORINE; HIV-1; HIV-2; HUMANS; PROTEIN BINDING; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; MIRIDAE;

EID: 74449092468     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.10.009     Document Type: Article

References (19)

1. Baba M., Pauwels R., Balzarini J., Arnout J., Desmyter J., and De Clercq E. Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 6132-6136
2. Bartz S.R., Hohenwalter E., Hu M.K., Rich D.H., and Malkovsky M. Inhibition of human immunodeficiency virus replication by nonimmunosuppressive analogs of cyclosporin A. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 5381-5385
3. Berthoux L., Sebastian S., Sokolskaja E., and Luban J. Lv1 inhibition of human immunodeficiency virus type 1 is counteracted by factors that stimulate synthesis or nuclear translocation of viral cDNA. J. Virol. 78 (2004) 11739-11750
4. Billich A., Hammerschmid F., Peichl P., Wenger R., Zenke G., Quesniaux V., and Rosenwirth B. Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus (HIV) type 1: interference with HIV protein-cyclophilin A interactions. J. Virol. 69 (1995) 2451-2461
5. Briggs C.J., Ott D.E., Coren L.V., Oroszlan S., and Tozser J. Comparison of the effect of FK506 and cyclosporin A on virus production in H9 cells chronically and newly infected by HIV-1. Arch. Virol. 144 (1999) 2151-2160
6. Chatterji U., Bobardt M.D., Stanfield R., Ptak R.G., Pallansch L.A., Ward P.A., Jones M.J., Stoddart C.A., Scalfaro P., Dumont J.M., Besseghir K., Rosenwirth B., and Gallay P.A. Naturally occurring capsid substitutions render HIV-1 cyclophilin A independent in human cells and TRIM-cyclophilin-resistant in Owl monkey cells. J. Biol. Chem. 280 (2005) 40293-40300
7. De Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int. J. Antimicrob. Agents 33 (2009) 307-320
8. Franke E.K., and Luban J. Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. Virology 222 (1996) 279-282
9. Franke E.K., Yuan H.E., and Luban J. Specific incorporation of cyclophilin A into HIV-1 virions. Nature 372 (1994) 359-362
10. Jordan A., Bisgrove D., and Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J. 22 (2003) 1868-1877
11. Jordan A., Defechereux P., and Verdin E. The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. EMBO J. 20 (2001) 1726-1738
12. Karpas A., Lowdell M., Jacobson S.K., and Hill F. Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK 506. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 8351-8355
13. Mitsuya H., Looney D.J., Kuno S., Ueno R., Wong-Staal F., and Broder S. Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science 240 (1988) 646-649
14. Noser J.A., Towers G.J., Sakuma R., Dumont J.M., Collins M.K., and Ikeda Y. Cyclosporine increases human immunodeficiency virus type 1 vector transduction of primary mouse cells. J. Virol. 80 (2006) 7769-7774
15. Paeshuyse J., Kaul A., De Clercq E., Rosenwirth B., Dumont J.M., Scalfaro P., Bartenschlager R., and Neyts J. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 43 (2006) 761-770
16. Pauwels R., Andries K., Desmyter J., Schols D., Kukla M.J., Breslin H.J., Raeymaeckers A., Van Gelder J., Woestenborghs R., Heykants J., et al. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343 (1990) 470-474
17. Ptak R.G., Gallay P.A., Jochmans D., Halestrap A.P., Ruegg U.T., Pallansch L.A., Bobardt M.D., de Béthune M.P., Neyts J., De Clercq E., Dumont J.M., Scalfaro P., Besseghir K., Wenger R.M., and Rosenwirth B. Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent. Antimicrob. Agents Chemother. 52 (2008) 1302-1317
18. Rosenwirth B., Billich A., Datema R., Donatsch P., Hammerschmid F., Harrison R., Hiestand P., Jaksche H., Mayer P., Peichl P., et al. Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. Antimicrob. Agents Chemother. 38 (1994) 1763-1772
19. Yoo S., Myszka D.G., Yeh C., McMurray M., Hill C.P., and Sundquist W.I. Molecular recognition in the HIV-1 capsid/cyclophilin A complex. J. Mol. Biol. 269 (1997) 780-795